Haleon Reports Solid Q3 Growth, Reaffirms FY25 Guidance

Haleon (LON: HLN) delivered a robust third-quarter trading statement, showcasing healthy organic revenue growth and reaffirming its financial year 2025 guidance. The consumer healthcare giant's performance was primarily fueled by strong showings in its Oral Health and Vitamins, Minerals, and Supplements (VMS) categories.

Reported revenue for the three months ended September 30, 2025, reached £2,799 million, with organic revenue growth of 3.4%. This growth was driven by a 1.8% increase in price and a 1.6% uptick in volume/mix. These figures indicate a balanced approach to revenue generation, leveraging both pricing strategies and increased consumer demand.

Geographically, EMEA & LatAm led the charge with 5.3% organic revenue growth, followed closely by Asia-Pacific at 5.1%. North America, while positive, saw more modest growth of 0.4%, reflecting a potentially more challenging consumer environment in that region.

Oral Health stood out as the star performer, achieving an impressive 6.9% organic revenue growth. VMS also contributed significantly, with 4.9% growth, bolstered by the strength of the Centrum brand in EMEA & LatAm. Pain Relief saw a respectable 3.7% increase, while Respiratory Health experienced a decline of 1.8%, likely influenced by seasonal factors.

Haleon continues to prioritize returning capital to shareholders. Year-to-date, the company has returned approximately £1.1 billion through share buybacks and dividends, demonstrating a commitment to shareholder value. This includes a completed £500 million share buyback program allocated for 2025.

CEO Brian McNamara stated, “We delivered a good performance in the third quarter. All regions delivered positive organic revenue growth, driven by strong in-market execution and the continued roll-out of our innovation pipeline… We are on track to deliver our FY guidance and remain confident in our medium-term outlook.”

Looking ahead, Haleon reiterates its FY25 guidance, expecting organic revenue growth of around 3.5%, assuming a normal cold and flu season. The company also anticipates high-single-digit organic operating profit growth. However, the net impact of M&A is expected to dilute FY25 revenue and adjusted operating profit by approximately 2.0% and 5.5%, respectively, due to prior disposals.